Amgen's revenue has grown from $9.2B in Q4 2024 to $9.9B in the most recent Q4 2025 period, representing a 10.7% year-over-year increase. More impressively, the company's net income has climbed from $5.84B to $14.23B over the same time frame, a 144.2% jump. Amgen's net margin has expanded from 21.0% in Q4 2024 to 21.0% in Q4 2025, indicating stable profitability. The company's return on invested capital (ROIC) remains strong at 13.9%, well above its cost of capital. These consistent revenue gains, stable margins, and high ROIC suggest Amgen is executing well and leveraging its competitive position in the biopharmaceutical industry. The data indicates the company is generating increasing amounts of free cash flow to reinvest in the business and return to shareholders. Amgen currently trades at a price-to-earnings ratio of 26.7x based on the last four quarters of earnings, which appears reasonable relative to the S&P 500 average of 21.8x. This valuation, combined with Amgen's solid growth and profitability profile, makes the stock appealing from a quality-at-a-reasonable-price perspective. Given Amgen's fundamental momentum, I believe the stock can reach $420 per share over the next 180 days, implying a 10.7% upside from the current price of $379.33. This target is supported by the company's ability to continue expanding earnings at a double-digit pace, as well as the potential for multiple expansion as investors recognize Amgen's reasonable valuation relative to the broader market.

1 Reply

Research these companies